Documentation Centre

 

 

  of 80 Next page

Go to page: of

Screenshot Date Categories Title Author Format
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-1971 February 07, 2018 Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-1971 Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators Key Publications
Very low LDL-cholesterol concentrations achieved: which target is next? Lancet. 2017;390:1930-1931 February 07, 2018 Very low LDL-cholesterol concentrations achieved: which target is next? Lancet. 2017;390:1930-1931 Hovingh GK, Boekholdt SM, Stroes ES Key Publications
Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol. 2017;14:635-636 January 24, 2018 Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol. 2017;14:635-636 Holmes MV, Smith GD. Key Publications
Hypertension control in adults with diabetes mellitus and recurrent cardiovascular events: global results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin. Hypertension. 2017;70:907-914 January 23, 2018 Hypertension control in adults with diabetes mellitus and recurrent cardiovascular events: global results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin. Hypertension. 2017;70:907-914 Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group Key Publications
Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-2160 January 10, 2018 Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-2160 Thomopoulos C, Parati G, Zanchetti A Key Publications
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239 January 08, 2018 Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239 Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group Key Publications
Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217-1227 January 08, 2018 Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217-1227 HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ Key Publications
Effects of dietary sodium on metabolites: the Dietary Approaches to Stop Hypertension (DASH)-Sodium Feeding Study. Am J Clin Nutr. 2017;106:1131-1141 November 29, 2017 Effects of dietary sodium on metabolites: the Dietary Approaches to Stop Hypertension (DASH)-Sodium Feeding Study. Am J Clin Nutr. 2017;106:1131-1141 Derkach A, Sampson J, Joseph J, Playdon MC, Stolzenberg-Solomon RZ Key Publications
High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis. 2017;263:104-111 November 22, 2017 High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis. 2017;263:104-111 Liu HH, Guo YL, Wu NQ, Zhu CG, Gao Y, Qing P, Li S, Zhao X, Zhang Y, Sun D, Liu G, Dong Q, Li JJ Key Publications
High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis. 2017;263:104-111 November 22, 2017 High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis. 2017;263:104-111 Liu HH, Guo YL, Wu NQ, Zhu CG, Gao Y, Qing P, Li S, Zhao X, Zhang Y, Sun D, Liu G, Dong Q, Li JJ Key Publications

  of 80 Next page

Go to page: of